Institutional Biosafety Committee

CDC Institutional Biosafety Committee (IBC) Meeting Minutes

Date: March 20, 2026
Time: 10:30 AM – 12:00 PM
Location: MS Teams meeting

Member	Attendance	Member	Attendance
1. NCEZID/DVBD1	☒	13. NCEZID/DCLSR2	☐
2. NCIRD/DVD	☒	14. IOD/OLSS3	☒
3. NCEZID/DHCPP1	☒	16. NCEZID/DCLSR3	☒
4. IOD/OLSS1	☒	17. NCEZID/OD	☒
5. OCOO/OSSAM/OHC	☐	18. IOD/OLSS4	☒
6. NCEZID/DVBD2	☒	19. NCHHSTP/DHP2	☒
7. IOD/OLSS2	☒	20. Outside Member/Atlanta1	☒
8. NCHHSTP/DHP1	☒	21. Outside Member/Atlanta2	☒
9. NCHHSTP/DTE	☐	22. Outside Member/Fort Collins	☒
10. NCIRD/ID	☐	23. Outside Member/Puerto Rico	☐
11. NCIRD/CORVD	☒	24. CDC/GHC/OD	☒
12. NCEZID/DCLSR1	☒	**Visitor(s)**	**4**

Agenda

1. **10:32 am EST-** Welcome
2. Review and approval of **February 27, 2026** Meeting Minutes.
3. Review of IBC registrations:
    1) IBC-2025-269 Renewal
    2) IBC-2026-306 Renewal
    3) IBC-2026-307 Renewal
    4) IBC-2026-308 Original
    5) IBC-2026-309 Renewal
    6) IBC-2026-310 Renewal
    7) IBC-2026-311 Renewal
4. Other Business

Principal Discussion

- Quorum confirmed.
- Meeting called to order at 10:32 am
- Review and approval of **February 27, 2026** Meeting Minutes.
- Review of IBC Registrations
- Other Business

Review of IBC Registrations

1. IBC-2025-269 **Renewal**

General Project Description: The goal of this project is to develop a reverse genetic system for Crimean Congo Hemorrhagic Fever virus in order to determine site-specific molecular determinants that lead to high pathogenicity in humans and further develop CCHF VRP vaccine.
Approximate percentage of the viral genome used: >2/3
Applicable Sec of NIH Guidelines: III-D-1-a, Section III-D-1-c, Section III-D-3-a, Section III-D-3-c, III-D-4-a, III-D-4-b
Required biological containment level for the work to be implemented: BSL-2, BSL-4
General Points Discussed:
- **Section 1.3:** Please specify the year of VRP generation.
- **Section 2.6:** Please indicate the BSL level for each pathogen.
- **Section 4:** Remove room number but include campus name and Bldg. name.

Committee Action: Approved with changes

2. IBC-2026-306 **Renewal**
General Project Description: The World Health Organization (WHO) Global Action Plan version 4 (GAPIV) allows for the use of poliovirus mutant strains (S19 strains) outside of GAPIV containment requirements. There are six S19 strains: one for each Sabin capsid sequence (1, 2, and 3) and one for each wild type capsid (Mahoney, MEF-1, and Saukett). The S19 strains are highly attenuated and cannot infect or replicate in non-human primates, while retaining ability to replicate in cell culture. We will be using the six strains of S19 to perform poliovirus microneutralization assays to assess poliovirus antibody titers and for cell sensitivity testing. We will compare microneutralization (serology) results using the S19 strains to those using Sabin and wild type strains.
Approximate percentage of the viral genome used: >2/3
Applicable Sec of NIH Guidelines: III-D-3-a
Required biological containment level for the work to be implemented: BSL-2
General Points Discussed:
- **Section 2.7c:** Remove S19 strain as helper virus.

Committee Action: Approved with changes

3. IBC-2026-307 **Renewal**
General Project Description: Mammalian expression plasmids encoding the genes for respiratory syncytial virus fusion and glycoprotein will be synthesized. The genes will be codon optimized, truncated so they are soluble and secreted, and epitope tags will be added for purification. These plasmids will be used to transiently transfect HEK-293 mammalian cell lines. Fusion and glycoprotein will be purified from those transfections with affinity resin, and will be used to examine antibody responses in human sera.
Approximate percentage of the viral genome used: <1/2
Applicable Sec of NIH Guidelines: III-D-2-a, III-E-1, III-F-8
Required biological containment level for the work to be implemented: BSL-2
General Points Discussed:
- **Section 4:** Remove room number but include campus name and Bldg. number.

Committee Action: Approved with changes

4. IBC-2026-308 **Original**
General Project Description: Recombinant flaviviruses, including but not limited to dengue viruses (DENV), West Nile virus (WNV), Zika virus (ZIKV), Yellow fever virus (YFV), Usutu virus (USUV), tick-borne encephalitis virus (TBEV), Japanese encephalitis virus (JEV), St. Louis encephalitis virus (SLEV) and Powassan virus (POWV), their mutant viruses, closely related viruses, and their chimeric viruses are used for study of virus replication, vaccine development, and diagnostic assay development.
Approximate percentage of the viral genome used: >2/3
Applicable Sec of NIH Guidelines: III-D-1-a, III-D-1-b, III-D-2-a, III-D-3-a

Required biological containment level for the work to be implemented: BSL-2, BSL-3
General Points Discussed: N/A
Committee Action: Approved as written

5. IBC-2026-309 **Renewal**
General Project Description: We will use synthetic biology to generate infectious clones of parechovirus A3 (PeV-A3). Infectious clones will be used to identify the molecular interactions between PeV-A3 and the antivirals posaconazole (POS) and itraconazole (ITC). We identified these compounds to have antiviral activity against PeV-A3 but how they impair the virus is unknown. A variety of cell-culture based assays will be used to assess Pev-A3 biology, including infectivity, replication kinetics, fitness, and thermal stability of the infectious clones in the in the absence or presence of POS and ITC. We will attempt to identify PeV-A3 viruses that are resistant to POS and ITC to better define how the drugs impair infection.
Approximate percentage of the viral genome used: >2/3
Applicable Sec of NIH Guidelines: III-D-1, III-D-2-a, III-D-3
Required biological containment level for the work to be implemented: BSL-2
General Points Discussed:
   - **Section 3:** Remove the HEK293 cell line and include the virus receiving recombinant molecules instead.

Committee Action: Approved with changes

6. IBC-2026-310 **Renewal**
General Project Description: The research proposed is to develop control strains for antimicrobial susceptibility testing using attenuated, select agent (SA) - excluded strains. The control strains will be used to ensure that susceptibility tests are performing as expected for each species/drug combination.
Approximate percentage of the viral genome used: Not Applicable
Applicable Sec of NIH Guidelines: III-D-1-a, III-D-8
Required biological containment level for the work to be implemented: BSL-2
General Points Discussed: N/A
Committee Action: Approved as written

7. IBC-2026-311 **Renewal**
General Project Description: Synthetic biology will be used to generate infectious clones of enterovirus D68 (EV-D68), a ubiquitous human respiratory virus. Clones will be identical by nucleotide sequence to viral strains isolated from nasopharyngeal swabs of patients with an upper respiratory infection in various locations across the United States. Clones will be used to investigate the basic biology of the virus, including strain-specific differences in virus-host interactions and pathogenesis. The focus of these studies will be infection in cell culture models.
Approximate percentage of the viral genome used: >2/3
Applicable Sec of NIH Guidelines: III-D-2-a, III-D-3-a
Required biological containment level for the work to be implemented: BSL-2
General Points Discussed: N/A
Committee Action: Approved as written

Other Business

- **Committee Rapporteur (CR)**
  - Starting April 2026

- The CR role shall be rotated among the voting members
- The CR shall lead discussion of IBC registrations during the full committee meeting
- Initially, each CR will be assigned fewer than 3 registrations

- **Revise Training Course**
  - IBC Requirements for Working with Recombinant or Synthetic Nucleic Acid Molecules
- **PULSE Feedback/Questions**
  - Collecting feedback for critical items; implementation of new features will be postponed until after July
  - Please share questions/comments to the IBC mailbox or PULSE support desk
- **Meeting Agenda**
  - Any committee member can propose agenda items for discussion
  - The IBC Administrator finalizes the meeting agenda through check-in meetings with the Chairs
- **Meeting adjourned at 11:35 am**

REYNOLDS M. SALERNO -S

Digitally signed by REYNOLDS M. SALERNO -S
Date: 2026.04.20 11:33:36 -04'00'

_____

Reynolds M Salerno, PhD
Director, Office of Laboratory Systems and Response